Navigation Links
UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
Date:10/31/2007

UCLA's California NanoSystems Institute (CNSI) and the University of Tokyo's Center for NanoBio Integration (CNBI) will jointly sponsor an international symposium on nanobiotechnology at UCLA Nov. 12.

The CNSI-CNBI Symposium on NanoBiotechnology, which will be held in the auditorium of UCLA's new CNSI building, an 188,000-square-foot structure dedicated to nano-scale research, will feature keynote speakers from the Sidney Kimmel Cancer Center in San Diego, the National Cancer Institute's Alliance for Nanotechnology in Cancer, the Lawrence Berkeley National Laboratory and the National Science Foundation.

The symposium will begin with remarks from UCLA Chancellor Gene Block and University of Tokyo President Hiroshi Komiyama, followed by special presentations on biotechnology and biomedical topics by renowned researchers from the Japanese National Institute for Materials Science, the CNBI, the CNSI and the David Geffen School of Medicine at UCLA.

Nanobiotechnology has emerged in recent years as an important new field of research especially the area of nanomedicine. Nano-scale cancer research, for example, has produced new means of detection, diagnosis and drug delivery. Speakers from disciplines including biology, medicine, chemistry, physics and bioengineering will highlight such advances, which are transforming medical research today and are expected to have a dramatic impact on medical practices in the future.

A special panel discussion titled "Bridging the Gap: Bringing NanoBiology to the Healthcare Industry" will illuminate the importance of developing novel nanomaterials and nano-scale methods for biological research and medical application and will highlight the important research initiatives featured throughout the symposium.

The symposium, organized by CNSI member Fuyu Tamanoi, UCLA professor of microbiology, immunology and molecular genetics and director of the signal transduction and therapeutics program area at UCLA's Jonsson Comprehensive Cancer Center, will also feature in-depth scientific panels and discussion groups focusing on nanomaterials, nanodetection and cell interatcion; nanodevices and microscopic methods; and nanomedicine and nanotherapy.

The symposium's focus nanobiotechnology reflects important strengths of both UCLA and the University of Tokyo. Located in technology research hubs, both universities have strong medical, engineering and physical science schools and through their interdisciplinary nano-research centers play significant roles in the international science community. This is the first of what will be an ongoing series of international conferences at CNSI.

The symposium has received additional sponsorship from Japan's National Institute of Materials Science; the University of California Discovery Program; Mattel Children's Hospital UCLA; UCLA's Jonsson Comprehensive Cancer Center; the David Geffen School of Medicine at UCLA; the UCLA Department of Microbiology, Immunology and Molecular Genetics; and Wako Pure Chemical Industries Ltd.

For additional information including the complete symposium agenda, a list of speakers and abstracts visit www.cnsi.ucla.edu/conferences/nanobio. The event is free, but registration is encouraged, as space is limited.


'/>"/>

Contact: Jennifer Marcus
jmarcus@cnsi.ucla.edu
310-267-4839
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. John Hopkins Hospitals- Now at Tokyo
2. Traders Smell Something Fishy in Tokyo Market Move
3. Armani to Launch First Spa in Tokyo
4. Researchers at Cornell University as been reported using research fund by false claims
5. A new study by John Hopkins University proposes formula for good health
6. James Cook University urges more medical seats
7. Pill splitting program of University of Michigan can save money
8. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
9. Yale University guidelines for Physicians and Pharmaceutical industry
10. $ 1.7 Million NYSTAR Award for Binghamton University to Flex Electronics Research Muscle.
11. Florida State University declares a breathtaking study which might solve the Hepatitis C Virus maze and find a cure!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Peoria, IL (PRWEB) , ... May 22, 2017 ... ... HealthCare, is part of a larger group investing in InsightRX, an early stage ... a patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund ...
(Date:5/21/2017)... FL (PRWEB) , ... May 20, 2017 , ... Pot. ... it, find it, review it, and share its attributes like never before. More than ... directory to connect cannabis enthusiasts to stores, strains, products – and for the first ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... longer than six months since you've seen a dentist, it's time for a ... and getting x-rays once per year. , Dental checkups are a relatively easy ...
(Date:5/19/2017)... ... May 19, 2017 , ... Springfield, Vermont-based law firm ... Titled " Ten Good Reasons To Hire An Experienced Personal Injury Attorney, " the ... an accident or injury. As the article says. if someone is injured due ...
(Date:5/19/2017)... ... 19, 2017 , ... As a groundbreaking surgeon on the frontline of prostate ... screenings. Early detection of the disease, he says, can make a world of difference. ... , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: